img

Global Long-Acting Injectable (LAI) Antipsychotic Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Long-Acting Injectable (LAI) Antipsychotic Market Research Report 2024

Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
According to MRAResearch’s new survey, global Long-Acting Injectable (LAI) Antipsychotic market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Long-Acting Injectable (LAI) Antipsychotic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Long-Acting Injectable (LAI) Antipsychotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
Sumitomo Dainippon Pharma
Segment by Type
Aripiprazole
Fluphenazine
Haloperidol
Others

Segment by Application


Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Long-Acting Injectable (LAI) Antipsychotic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Aripiprazole
1.2.3 Fluphenazine
1.2.4 Haloperidol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Perspective (2018-2033)
2.2 Long-Acting Injectable (LAI) Antipsychotic Growth Trends by Region
2.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Region (2018-2023)
2.2.3 Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Region (2024-2033)
2.3 Long-Acting Injectable (LAI) Antipsychotic Market Dynamics
2.3.1 Long-Acting Injectable (LAI) Antipsychotic Industry Trends
2.3.2 Long-Acting Injectable (LAI) Antipsychotic Market Drivers
2.3.3 Long-Acting Injectable (LAI) Antipsychotic Market Challenges
2.3.4 Long-Acting Injectable (LAI) Antipsychotic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue
3.1.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue (2018-2023)
3.1.2 Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Players (2018-2023)
3.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Injectable (LAI) Antipsychotic Revenue
3.4 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio
3.4.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2022
3.5 Long-Acting Injectable (LAI) Antipsychotic Key Players Head office and Area Served
3.6 Key Players Long-Acting Injectable (LAI) Antipsychotic Product Solution and Service
3.7 Date of Enter into Long-Acting Injectable (LAI) Antipsychotic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Injectable (LAI) Antipsychotic Breakdown Data by Type
4.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Type (2018-2023)
4.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Type (2024-2033)
5 Long-Acting Injectable (LAI) Antipsychotic Breakdown Data by Application
5.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Application (2018-2023)
5.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2033)
6.2 North America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
6.4 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2033)
7.2 Europe Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
7.4 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2033)
8.2 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023)
8.4 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2033)
9.2 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
9.4 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2033)
10.2 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
10.4 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Detail
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Introduction
11.1.4 Alkermes Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.1.5 Alkermes Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Detail
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Introduction
11.2.4 Eli Lilly and Company Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.2.5 Eli Lilly and Company Recent Development
11.3 Janssen Global Services, LLC
11.3.1 Janssen Global Services, LLC Company Detail
11.3.2 Janssen Global Services, LLC Business Overview
11.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Introduction
11.3.4 Janssen Global Services, LLC Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.3.5 Janssen Global Services, LLC Recent Development
11.4 Abilify Maintena
11.4.1 Abilify Maintena Company Detail
11.4.2 Abilify Maintena Business Overview
11.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Introduction
11.4.4 Abilify Maintena Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.4.5 Abilify Maintena Recent Development
11.5 Haldol
11.5.1 Haldol Company Detail
11.5.2 Haldol Business Overview
11.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Introduction
11.5.4 Haldol Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.5.5 Haldol Recent Development
11.6 Otsuka Pharmaceutical
11.6.1 Otsuka Pharmaceutical Company Detail
11.6.2 Otsuka Pharmaceutical Business Overview
11.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Introduction
11.6.4 Otsuka Pharmaceutical Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.6.5 Otsuka Pharmaceutical Recent Development
11.7 Aristada
11.7.1 Aristada Company Detail
11.7.2 Aristada Business Overview
11.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Introduction
11.7.4 Aristada Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.7.5 Aristada Recent Development
11.8 Prolixin
11.8.1 Prolixin Company Detail
11.8.2 Prolixin Business Overview
11.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Introduction
11.8.4 Prolixin Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.8.5 Prolixin Recent Development
11.9 Sumitomo Dainippon Pharma
11.9.1 Sumitomo Dainippon Pharma Company Detail
11.9.2 Sumitomo Dainippon Pharma Business Overview
11.9.3 Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Introduction
11.9.4 Sumitomo Dainippon Pharma Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.9.5 Sumitomo Dainippon Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Aripiprazole
Table 3. Key Players of Fluphenazine
Table 4. Key Players of Haloperidol
Table 5. Key Players of Others
Table 6. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2018-2023)
Table 10. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2024-2033)
Table 12. Long-Acting Injectable (LAI) Antipsychotic Market Trends
Table 13. Long-Acting Injectable (LAI) Antipsychotic Market Drivers
Table 14. Long-Acting Injectable (LAI) Antipsychotic Market Challenges
Table 15. Long-Acting Injectable (LAI) Antipsychotic Market Restraints
Table 16. Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Players (2018-2023)
Table 18. Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2022)
Table 19. Ranking of Global Top Long-Acting Injectable (LAI) Antipsychotic Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Long-Acting Injectable (LAI) Antipsychotic Product Solution and Service
Table 23. Date of Enter into Long-Acting Injectable (LAI) Antipsychotic Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Type (2018-2023)
Table 27. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Type (2024-2033)
Table 29. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Application (2018-2023)
Table 31. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Application (2024-2033)
Table 33. North America Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2033) & (US$ Million)
Table 48. Alkermes Company Detail
Table 49. Alkermes Business Overview
Table 50. Alkermes Long-Acting Injectable (LAI) Antipsychotic Product
Table 51. Alkermes Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 52. Alkermes Recent Development
Table 53. Eli Lilly and Company Company Detail
Table 54. Eli Lilly and Company Business Overview
Table 55. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product
Table 56. Eli Lilly and Company Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 57. Eli Lilly and Company Recent Development
Table 58. Janssen Global Services, LLC Company Detail
Table 59. Janssen Global Services, LLC Business Overview
Table 60. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product
Table 61. Janssen Global Services, LLC Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 62. Janssen Global Services, LLC Recent Development
Table 63. Abilify Maintena Company Detail
Table 64. Abilify Maintena Business Overview
Table 65. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product
Table 66. Abilify Maintena Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 67. Abilify Maintena Recent Development
Table 68. Haldol Company Detail
Table 69. Haldol Business Overview
Table 70. Haldol Long-Acting Injectable (LAI) Antipsychotic Product
Table 71. Haldol Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 72. Haldol Recent Development
Table 73. Otsuka Pharmaceutical Company Detail
Table 74. Otsuka Pharmaceutical Business Overview
Table 75. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product
Table 76. Otsuka Pharmaceutical Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 77. Otsuka Pharmaceutical Recent Development
Table 78. Aristada Company Detail
Table 79. Aristada Business Overview
Table 80. Aristada Long-Acting Injectable (LAI) Antipsychotic Product
Table 81. Aristada Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 82. Aristada Recent Development
Table 83. Prolixin Company Detail
Table 84. Prolixin Business Overview
Table 85. Prolixin Long-Acting Injectable (LAI) Antipsychotic Product
Table 86. Prolixin Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 87. Prolixin Recent Development
Table 88. Sumitomo Dainippon Pharma Company Detail
Table 89. Sumitomo Dainippon Pharma Business Overview
Table 90. Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Product
Table 91. Sumitomo Dainippon Pharma Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)
Table 92. Sumitomo Dainippon Pharma Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Type: 2022 VS 2033
Figure 3. Aripiprazole Features
Figure 4. Fluphenazine Features
Figure 5. Haloperidol Features
Figure 6. Others Features
Figure 7. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Application: 2022 VS 2033
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. Long-Acting Injectable (LAI) Antipsychotic Report Years Considered
Figure 13. Global Long-Acting Injectable (LAI) Antipsychotic Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Long-Acting Injectable (LAI) Antipsychotic Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region: 2022 VS 2033
Figure 16. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Players in 2022
Figure 17. Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2022
Figure 19. North America Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2033)
Figure 21. United States Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2033)
Figure 25. Germany Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2018-2033)
Figure 33. China Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2033)
Figure 41. Mexico Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2033)
Figure 45. Turkey Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Alkermes Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 48. Eli Lilly and Company Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 49. Janssen Global Services, LLC Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 50. Abilify Maintena Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 51. Haldol Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 52. Otsuka Pharmaceutical Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 53. Aristada Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 54. Prolixin Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 55. Sumitomo Dainippon Pharma Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries